FY2028 EPS Forecast for Wave Life Sciences Lifted by Analyst

Wave Life Sciences Ltd. (NASDAQ:WVE) – Research analysts at HC Wainwright boosted their FY2028 earnings per share (EPS) estimates for shares of Wave Life Sciences in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $1.27 per share for the year, up from their prior forecast of $1.23. HC Wainwright currently has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.06) per share.

Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.19). Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. The company had revenue of ($7.68) million during the quarter, compared to analysts’ expectations of $15.45 million.

A number of other equities research analysts have also recently commented on WVE. Raymond James raised Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and raised their price target for the company from $13.00 to $22.00 in a report on Wednesday, October 16th. B. Riley boosted their price target on Wave Life Sciences from $19.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, November 4th. JPMorgan Chase & Co. increased their price objective on shares of Wave Life Sciences from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, October 17th. Truist Financial boosted their target price on shares of Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Leerink Partners raised their target price on shares of Wave Life Sciences from $20.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $21.89.

Wave Life Sciences Price Performance

Shares of NASDAQ WVE opened at $15.00 on Friday. The stock has a market cap of $1.87 billion, a PE ratio of -13.51 and a beta of -1.20. Wave Life Sciences has a 1 year low of $3.50 and a 1 year high of $16.74. The firm has a fifty day moving average price of $10.40 and a 200-day moving average price of $7.41.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of WVE. Swiss National Bank grew its holdings in shares of Wave Life Sciences by 2.7% during the first quarter. Swiss National Bank now owns 156,500 shares of the company’s stock valued at $966,000 after buying an additional 4,100 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Wave Life Sciences by 35.0% in the first quarter. ProShare Advisors LLC now owns 21,764 shares of the company’s stock worth $134,000 after purchasing an additional 5,648 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Wave Life Sciences by 39.7% during the first quarter. Vanguard Group Inc. now owns 1,834,090 shares of the company’s stock worth $11,316,000 after purchasing an additional 521,665 shares during the period. Ameritas Investment Partners Inc. boosted its position in Wave Life Sciences by 50.2% in the first quarter. Ameritas Investment Partners Inc. now owns 7,334 shares of the company’s stock valued at $45,000 after buying an additional 2,451 shares during the last quarter. Finally, American International Group Inc. increased its holdings in Wave Life Sciences by 23.3% in the 1st quarter. American International Group Inc. now owns 36,241 shares of the company’s stock worth $224,000 after buying an additional 6,851 shares during the period. Institutional investors own 89.73% of the company’s stock.

Insider Buying and Selling

In related news, CFO Kyle Moran sold 17,146 shares of Wave Life Sciences stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total transaction of $154,314.00. Following the transaction, the chief financial officer now directly owns 19,777 shares of the company’s stock, valued at $177,993. This trade represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Paul Bolno sold 48,366 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $5.78, for a total value of $279,555.48. Following the sale, the chief executive officer now owns 359,059 shares of the company’s stock, valued at approximately $2,075,361.02. This represents a 11.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 400,822 shares of company stock valued at $5,221,768 over the last quarter. 29.10% of the stock is owned by corporate insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.